PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10713582-3 2000 Rivastigmine is an AChE inhibitor that is enzymatically cleaved by AChE, minimally metabolized by cytochrome P450 enzymes, has low protein binding, has a short plasma half-life, and a relatively short duration of action. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-23 10713582-3 2000 Rivastigmine is an AChE inhibitor that is enzymatically cleaved by AChE, minimally metabolized by cytochrome P450 enzymes, has low protein binding, has a short plasma half-life, and a relatively short duration of action. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 67-71 10641971-3 2000 Rivastigmine is classified as an intermediate-acting or pseudo-irreversible agent due to its long inhibition on AChE of up to 10 hours. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-116 11139819-0 1999 Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer"s disease: review and current status. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 39-59 10587286-9 1999 Inhibition of AChE in the CSF after rivastigmine administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours. Rivastigmine 36-48 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-18 10587286-12 1999 This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE. Rivastigmine 121-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 156-160 10587286-12 1999 This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE. Rivastigmine 121-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 156-160 10587286-12 1999 This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE. Rivastigmine 121-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 156-160 11139819-5 1999 Rivastigmine is a centrally-selective acetylcholinesterase inhibitor with a relatively long duration of action and is a "pseudo-irreversible" cholinesterase inhibitor due to slow dissociation of a carbamoyl derivative from the esteratic site of acetylcholinesterase. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 38-58 11139819-5 1999 Rivastigmine is a centrally-selective acetylcholinesterase inhibitor with a relatively long duration of action and is a "pseudo-irreversible" cholinesterase inhibitor due to slow dissociation of a carbamoyl derivative from the esteratic site of acetylcholinesterase. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 245-265 10362894-1 1999 Rivastigmine is a carbamate acetylcholinesterase (AChE) inhibitor with central selectivity. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-54 9737824-0 1998 Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer"s disease. Rivastigmine 25-37 acetylcholinesterase (Cartwright blood group) Homo sapiens 56-76 9758554-1 1998 Pseudo-irreversible AChE inhibition with rivastigmine]. Rivastigmine 41-53 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-24 9737824-2 1998 Both preclinical studies and studies in human volunteers have shown that rivastigmine induces substantially greater inhibition of AChE in the central nervous system (CNS) compartment than in the periphery (40% inhibition of central AChE compared with 10% inhibition of plasma butylcholinesterase in healthy volunteers). Rivastigmine 73-85 acetylcholinesterase (Cartwright blood group) Homo sapiens 130-134 9737824-2 1998 Both preclinical studies and studies in human volunteers have shown that rivastigmine induces substantially greater inhibition of AChE in the central nervous system (CNS) compartment than in the periphery (40% inhibition of central AChE compared with 10% inhibition of plasma butylcholinesterase in healthy volunteers). Rivastigmine 73-85 acetylcholinesterase (Cartwright blood group) Homo sapiens 232-236 9737824-3 1998 Moreover, rivastigmine preferentially inhibits the G1 enzymatic form of AChE, which predominates in the brains of patients with Alzheimer"s disease (AD). Rivastigmine 10-22 acetylcholinesterase (Cartwright blood group) Homo sapiens 72-76 9737824-4 1998 Evidence from animal studies also suggests that rivastigmine is a more potent inhibitor of AChE in the cortex and hippocampus, the brain regions most affected by AD. Rivastigmine 48-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 91-95 9737824-7 1998 The principal metabolite of rivastigmine has at least 10-fold lower activity against AChE compared with the parent drug. Rivastigmine 28-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 9737824-10 1998 Distribution of rivastigmine into the CNS is extensive, and inhibition of AChE in the cerebrospinal fluid is detectable 1.2 hours after oral dosing in both healthy volunteers and patients with AD. Rivastigmine 16-28 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-78 9737824-12 1998 Rivastigmine is inactivated during the process of interacting with and inhibiting AChE, and, in contrast to other AChE inhibitors, the hepatic cytochrome P-450 (CYP-450) system is not involved in the metabolism of rivastigmine. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 82-86 10363493-12 1999 CONCLUSIONS: Different studies carried out with the acetylcholinesterase inhibitors donepezil, rivastigmine and metriphonate have been effective in the control of the cognitive symptoms of Alzheimer disease in the initial or moderate phases of the disease. Rivastigmine 95-107 acetylcholinesterase (Cartwright blood group) Homo sapiens 52-72 9794506-1 1998 PURPOSE: SDZ ENA 713 (rivastigmine) is an acetylcholinesterase inhibitor intended for therapeutic use in Alzheimer"s disease. Rivastigmine 22-34 acetylcholinesterase (Cartwright blood group) Homo sapiens 42-62 9737824-1 1998 Rivastigmine (ENA 713, or carbamoylatine) is an acetylcholinesterase (AChE) inhibitor with brain-region selectivity and a long duration of action. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-68 9737824-1 1998 Rivastigmine (ENA 713, or carbamoylatine) is an acetylcholinesterase (AChE) inhibitor with brain-region selectivity and a long duration of action. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-74 9737824-1 1998 Rivastigmine (ENA 713, or carbamoylatine) is an acetylcholinesterase (AChE) inhibitor with brain-region selectivity and a long duration of action. Rivastigmine 14-21 acetylcholinesterase (Cartwright blood group) Homo sapiens 48-68 9737824-1 1998 Rivastigmine (ENA 713, or carbamoylatine) is an acetylcholinesterase (AChE) inhibitor with brain-region selectivity and a long duration of action. Rivastigmine 14-21 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-74 15616667-3 1998 Currently used AChE inhibitors are tacrine, donepezil hydrochloride, rivastigmine and metrifonate. Rivastigmine 69-81 acetylcholinesterase (Cartwright blood group) Homo sapiens 15-19 9576639-7 1998 CONCLUSION: Rapid, sustained, dose-dependent inhibition of CSF AChE suggests that SDZ ENA 713 has therapeutic potential in AD patients. Rivastigmine 86-93 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-67 7884403-1 1994 The pharmacological and clinical properties of a novel phenyl carbamate acetylcholinesterase (AChE) inhibitor, SDZ ENA 713 are described. Rivastigmine 111-122 acetylcholinesterase (Cartwright blood group) Homo sapiens 94-98 8248533-4 1993 The results presented with SDZ ENA 713 indicate that the disadvantages of AChE inhibitors might be overcome by improving CNS selectivity and thereby decreasing the peripheral cholinergic effects and toxicity. Rivastigmine 27-38 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-78 1776750-0 1991 Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Rivastigmine 57-64 acetylcholinesterase (Cartwright blood group) Homo sapiens 88-108 34911424-4 2021 Similar positive although variable results have also been found in volumetric measurements of the cortex and whole brain in patients with mild cognitive impairment as well as more advanced AD stages after treatments with all three currently available acetylcholinesterase (AChE) inhibitors (donepezil, rivastigmine, and galantamine). Rivastigmine 302-314 acetylcholinesterase (Cartwright blood group) Homo sapiens 251-271 34522196-2 2021 A significant decrease in acetylcholine level in the brain is common in most patients with Alzheimer"s disease, therefore acetylcholinesterase (AChE) inhibitors such as donepezil and rivastigmine are widely used for patients with limited therapeutic results and major side effects. Rivastigmine 183-195 acetylcholinesterase (Cartwright blood group) Homo sapiens 122-142 34522196-2 2021 A significant decrease in acetylcholine level in the brain is common in most patients with Alzheimer"s disease, therefore acetylcholinesterase (AChE) inhibitors such as donepezil and rivastigmine are widely used for patients with limited therapeutic results and major side effects. Rivastigmine 183-195 acetylcholinesterase (Cartwright blood group) Homo sapiens 144-148 34522196-10 2021 Conclusion and implications: The synthesized compounds demonstrated moderate to good AChE inhibitory effect with results higher than rivastigmine. Rivastigmine 133-145 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 34832918-0 2021 The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro. Rivastigmine 66-78 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-39 34832918-2 2021 Drugs that inhibit acetylcholinesterase (AChE), such as rivastigmine, are promising symptomatic treatments for AD. Rivastigmine 56-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-39 34832918-2 2021 Drugs that inhibit acetylcholinesterase (AChE), such as rivastigmine, are promising symptomatic treatments for AD. Rivastigmine 56-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-45 34832918-10 2021 However, to improve our understanding of the possible interaction of insulin and rivastigmine, or its target AChE, more in silico modelling and in vivo studies are needed. Rivastigmine 81-93 acetylcholinesterase (Cartwright blood group) Homo sapiens 109-113 34547176-0 2021 Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer"s Disease Treatment. Rivastigmine 21-33 acetylcholinesterase (Cartwright blood group) Homo sapiens 54-74 34547176-2 2021 Herein, we integrate computational and theoretical methodologies to unveil rivastigmine derivatives as dual inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) for Alzheimer"s disease (AD) management. Rivastigmine 75-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 122-142 34547176-2 2021 Herein, we integrate computational and theoretical methodologies to unveil rivastigmine derivatives as dual inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) for Alzheimer"s disease (AD) management. Rivastigmine 75-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 144-148 34285627-8 2021 Moreover, rivastigmine is considered a pseudo-irreversible compound with anti-AChE action, providing similar effects at the clinical level. Rivastigmine 10-22 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-82 34911424-4 2021 Similar positive although variable results have also been found in volumetric measurements of the cortex and whole brain in patients with mild cognitive impairment as well as more advanced AD stages after treatments with all three currently available acetylcholinesterase (AChE) inhibitors (donepezil, rivastigmine, and galantamine). Rivastigmine 302-314 acetylcholinesterase (Cartwright blood group) Homo sapiens 273-277 35455397-11 2022 Many oxadiazoles showed lower IC50 values against AChE than established drug rivastigmine. Rivastigmine 77-89 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-54 35624580-6 2022 Finally, we investigated the effects of an inhibitor (rivastigmine) on the AchE activity of the PGFET. Rivastigmine 54-66 acetylcholinesterase (Cartwright blood group) Homo sapiens 75-79 35563011-3 2022 The combination of rivastigmine and antipsychotic drugs (apart from PNF) enhanced AChE inhibition. Rivastigmine 19-31 acetylcholinesterase (Cartwright blood group) Homo sapiens 82-86 35595404-2 2022 Current pharmacological treatment includes acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine; however, only one-third of patients respond to treatment. Rivastigmine 100-112 acetylcholinesterase (Cartwright blood group) Homo sapiens 43-63 35446431-1 2022 INTRODUCTION: The beneficial effect of rivastigmine, an acetylcholinesterase inhibitor (AChEi), which increases levels of acetylcholine (ACh), was first reported in 2013. Rivastigmine 39-51 acetylcholinesterase (Cartwright blood group) Homo sapiens 56-76 33488178-2 2020 Food and Drug Administration (FDA) approved drugs donepezil, rivastigmine, tacrine and galantamine are AChE inhibitors and in the treatment of Alzheimer"s disease (AD) these drugs are currently prescribed. Rivastigmine 61-73 acetylcholinesterase (Cartwright blood group) Homo sapiens 103-107 32874532-1 2020 Background: Acetylcholinesterase inhibitors (AChEis) including donepezil, galantamine and rivastigmine are used to treat Alzheimer"s disease (AD). Rivastigmine 90-102 acetylcholinesterase (Cartwright blood group) Homo sapiens 12-32 32092302-3 2020 Rivastigmine is one of the most widely used AChE inhibitors. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 44-48 32443670-3 2020 Donepezil (DP) and rivastigmine tartrate (RT) are acetylcholinesterase (AChE) inhibitors and are used to treat symptomatic patients of mild to moderate AD. Rivastigmine 19-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 32443670-3 2020 Donepezil (DP) and rivastigmine tartrate (RT) are acetylcholinesterase (AChE) inhibitors and are used to treat symptomatic patients of mild to moderate AD. Rivastigmine 19-40 acetylcholinesterase (Cartwright blood group) Homo sapiens 72-76 32443670-3 2020 Donepezil (DP) and rivastigmine tartrate (RT) are acetylcholinesterase (AChE) inhibitors and are used to treat symptomatic patients of mild to moderate AD. Rivastigmine 42-44 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 32443670-3 2020 Donepezil (DP) and rivastigmine tartrate (RT) are acetylcholinesterase (AChE) inhibitors and are used to treat symptomatic patients of mild to moderate AD. Rivastigmine 42-44 acetylcholinesterase (Cartwright blood group) Homo sapiens 72-76 32414155-4 2020 The current AChE inhibitors (donepezil, rivastigmine, and galantamine) have short-acting mechanisms of action that result in dose-limiting toxicity and inadequate efficacy. Rivastigmine 40-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 12-16 31978679-3 2020 Compounds 4ah and 4bh proved to be more potent than the standard drug tacrine, rivastigmine and galantamine for AChE inhibition activity with IC50 value between 0.055 +- 0.143 microM and 0.017 +- 0.02 microM respectively. Rivastigmine 79-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 112-116 30673880-10 2019 There is a consensus on benefit of initiating any acetylcholinesterase inhibitor (ACHI: donepezil, rivastigmine, and galantamine) as a first line of treatment for psychosis in AD, as it may reduce and/or avoid the need for the use antipsychotics. Rivastigmine 99-111 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-70 32995249-1 2019 Rivastigmine is a non-competitive reversible inhibitor of acetylcholinesterase which is approved as one of the fi rst-line treatment options for Alzheimer"s disease. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-78 32995249-13 2019 rivastigmine, an acetylcholinesterase inhibitor, can precipitate an acute cholinergic crisis in cases of intoxication. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-37 31162119-4 2019 Acetylcholinesterase inhibitors (donepezil or rivastigmine) were studied in several double-blind placebo-controlled studies. Rivastigmine 46-58 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 30771282-8 2019 Both rivastigmine and 4-bis-nitrophenyl phosphate inhibited plasma esterase activities, suggesting that acetylcholinesterase and carboxylesterase largely contribute to ASA hydrolysis. Rivastigmine 5-17 acetylcholinesterase (Cartwright blood group) Homo sapiens 104-124 31942651-8 2020 The formulation demonstrated sustained release of rivastigmine tartrate for 7 days in vivo with promising biocompatibility and acetylcholinesterase inhibition efficacy for 14 days. Rivastigmine 50-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 127-147 28060207-10 2018 After rivastigmine treatment, AChE activity was notably lower throughout the cortex in both respondents and nonrespondents, without significant differences between them. Rivastigmine 6-18 acetylcholinesterase (Cartwright blood group) Homo sapiens 30-34 30343499-3 2018 Drugs, such as tacrine, rivastigmine, donepezil, and galantamine are known as acetylcholinesterase inhibitors. Rivastigmine 24-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-98 29777723-2 2018 Given that acetylcholinesterase inhibitors are also currently believed to have anti-inflammatory properties, the purpose of this study was to investigate the effect of acetylcholinesterase inhibitors (rivastigmine, donepezil) on cyclooxygenase activity and expression using the proinflammatory action of fluoride (F-) on cultured macrophages obtained from THP-1 monocytes. Rivastigmine 201-213 acetylcholinesterase (Cartwright blood group) Homo sapiens 11-31 29777723-2 2018 Given that acetylcholinesterase inhibitors are also currently believed to have anti-inflammatory properties, the purpose of this study was to investigate the effect of acetylcholinesterase inhibitors (rivastigmine, donepezil) on cyclooxygenase activity and expression using the proinflammatory action of fluoride (F-) on cultured macrophages obtained from THP-1 monocytes. Rivastigmine 201-213 acetylcholinesterase (Cartwright blood group) Homo sapiens 168-188 28617100-4 2018 Among them, compound 7 (IC50 for AChE = 0.82 +- 0.08 mumol L-1, IC50 for BuChE = 46.30 +- 3.26 mumol L-1) showed a potent activity and high selectivity compared with the positive control Rivastigmine (IC50 for AChE = 10.54 +- 0.86 mumol L-1, IC50 for BuChE = 0.26 +- 0.08 mumol L-1). Rivastigmine 187-199 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-37 30577562-1 2018 It has been reported that donepezil and rivastigmine, the acetylcholinesterase (AchE) inhibitors commonly used in the treatment of Alzheimer"s disease (AD), do not only inhibit AChE but also have antioxidant properties. Rivastigmine 40-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-78 30577562-1 2018 It has been reported that donepezil and rivastigmine, the acetylcholinesterase (AchE) inhibitors commonly used in the treatment of Alzheimer"s disease (AD), do not only inhibit AChE but also have antioxidant properties. Rivastigmine 40-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-84 30577562-1 2018 It has been reported that donepezil and rivastigmine, the acetylcholinesterase (AchE) inhibitors commonly used in the treatment of Alzheimer"s disease (AD), do not only inhibit AChE but also have antioxidant properties. Rivastigmine 40-52 acetylcholinesterase (Cartwright blood group) Homo sapiens 177-181 29527733-5 2018 The biological activity results revealed that all of the title compounds displayed higher AChE inhibitory activity than the reference compound, rivastigmine, and were selective for AChE. Rivastigmine 144-156 acetylcholinesterase (Cartwright blood group) Homo sapiens 181-185 28711758-1 2017 In this report we assessed by docking and molecular dynamics the binding mechanisms of three FDA-approved Alzheimer drugs, inhibitors of the enzyme acetylcholinesterase (AChE): donepezil, galantamine and rivastigmine. Rivastigmine 204-216 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-174 28827871-2 2017 Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients. Rivastigmine 41-53 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 28458525-0 2017 Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson"s disease dementia. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 51-71 28458525-2 2017 Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Rivastigmine 99-111 acetylcholinesterase (Cartwright blood group) Homo sapiens 159-163 28458525-5 2017 Additionally, we review the evidence supporting the use of dual AChE-BuChE inhibitory activity of rivastigmine as a therapeutic strategy in the treatment of neurological disorders, with a focus on the role of rivastigmine in subcortical dementias such as vascular dementia (VaD) and PDD. Rivastigmine 98-110 acetylcholinesterase (Cartwright blood group) Homo sapiens 64-68 28458525-7 2017 The available evidence from the literature suggests that the dual inhibition of AChE and BuChE may afford additional therapeutic potential of rivastigmine in subcortical dementias (subcortical VaD and PDD) with benefits on cognition and behavioral symptoms. Rivastigmine 142-154 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-84 27073702-3 2016 Rivastigmine is a reversible and competitive inhibitor of acetylcholinesterase and butyrylcholinesterase used for symptomatic treatment of Alzheimer dementia and Parkinson"s disease. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-78 30183230-2 2017 Currently, drugs that are used symptomatically in the treatment of AD include acetylcholinesterase inhibitors (AChEIs) (rivastigmine, galantamine, donepezil) and N-methyl D-aspartate (NMDA) receptor antagonist (memantine). Rivastigmine 120-132 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-98 27597816-6 2016 Acetylcholinesterase (AChE) inhibitors are the drugs preferentially used in AD and that one of these, rivastigmine, is licensed also for PD. Rivastigmine 102-114 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 27597816-6 2016 Acetylcholinesterase (AChE) inhibitors are the drugs preferentially used in AD and that one of these, rivastigmine, is licensed also for PD. Rivastigmine 102-114 acetylcholinesterase (Cartwright blood group) Homo sapiens 22-26 26947959-7 2016 Compounds indicated as 3b, 3d, 3l and 3n showed the best AChE inhibitory activity of all the evaluated compounds and were up to tenfold more potent than standard drug rivastigmine. Rivastigmine 167-179 acetylcholinesterase (Cartwright blood group) Homo sapiens 57-61 26795874-3 2016 In the ReSPonD trial we aimed to assess whether ameliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce gait variability. Rivastigmine 126-138 acetylcholinesterase (Cartwright blood group) Homo sapiens 95-115 28635795-3 2016 To overcome the cholinergic insufficiency, acetylcholinesterase inhibitors (rivastigmine, donepezil and galantamine) are primarily used. Rivastigmine 76-88 acetylcholinesterase (Cartwright blood group) Homo sapiens 43-63 26264921-5 2015 Currently, acetylcholinesterase (AChE) inhibitors, such as donepezil, rivastigmine and galantamine are used to treat mild to moderate AD. Rivastigmine 70-82 acetylcholinesterase (Cartwright blood group) Homo sapiens 11-31 26642212-5 2015 A disproportionately higher frequency of reports of death as an adverse event for rivastigmine, compared to the other acetylcholinesterase inhibiting drugs, was observed in both the FAERS (ROR = 3.42; CI95% = 2.94-3.98; P<0.0001) and CVARD (ROR = 3.67; CI95% = 1.92-7.00; P = 0.001) databases. Rivastigmine 82-94 acetylcholinesterase (Cartwright blood group) Homo sapiens 118-138 26664715-5 2015 In this case series report, we present the effect of rivastigmine, an acetylcholinesterase inhibitor, on cognitive impairment in three older, severely depressed patients during or after a course of ECT. Rivastigmine 53-65 acetylcholinesterase (Cartwright blood group) Homo sapiens 70-90 25904872-4 2015 Both patients were successfully treated with the acetylcholinesterase inhibitor rivastigmine. Rivastigmine 80-92 acetylcholinesterase (Cartwright blood group) Homo sapiens 49-69 26455564-4 2015 The mostly used therapy of Alzheimer disease is based on enhancing cholinergic function using inhibitors of acetylcholinesterase like rivastigmine, donepezil or galantamine. Rivastigmine 134-146 acetylcholinesterase (Cartwright blood group) Homo sapiens 108-128 26264921-5 2015 Currently, acetylcholinesterase (AChE) inhibitors, such as donepezil, rivastigmine and galantamine are used to treat mild to moderate AD. Rivastigmine 70-82 acetylcholinesterase (Cartwright blood group) Homo sapiens 33-37 25082512-3 2014 Among all the compounds, 6a demonstrated the most potent AChE inhibition with IC50 value of 0.097muM, which is about 20-fold than that of rivastigmine. Rivastigmine 138-150 acetylcholinesterase (Cartwright blood group) Homo sapiens 57-61 25260958-3 2014 The most promising compound 4a (IC50: 4.68 mumol/L) was 2-fold more potent than Rivastigmine against AChE (IC50: 10.54 mumol/L) and showed a high selectivity for AChE over BuChE (ratio: 4.35). Rivastigmine 80-92 acetylcholinesterase (Cartwright blood group) Homo sapiens 101-105 25205193-3 2014 Moreover, the most promising compound 8 was 2-fold more active than rivastigmine, a well-known AChE inhibitor. Rivastigmine 68-80 acetylcholinesterase (Cartwright blood group) Homo sapiens 95-99 25202788-5 2014 In this connection, the efficacy of acetylcholinesterase inhibitors: galantamine (reminil),neuromidin, rivastigmine in the treatment of PD patients with dementia is discussed. Rivastigmine 103-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 36-56 24797332-1 2014 Rivastigmine is a non-competitive inhibitor of both acetylcholinesterase (AChE) and butylcholinesterase (BuChE) used to treat mild to moderate dementia in Alzheimer"s disease (AD) patients. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 52-72 24797332-1 2014 Rivastigmine is a non-competitive inhibitor of both acetylcholinesterase (AChE) and butylcholinesterase (BuChE) used to treat mild to moderate dementia in Alzheimer"s disease (AD) patients. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-78 24774720-5 2014 We propose that oral form acetylcholinesterase inhibitors (donepezil, galantamine and rivastigmine) also posses the effect of inhibiting GABA receptors, and act as indirect antagonist, to be applied in the rapid detoxification treatment of BZDs and Z-drug dependence. Rivastigmine 86-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 26-46 24504487-4 2014 Nocturnal visual hallucinations persisted in spite of reduced dopaminergic medication and sequential treatment with atypical antipsychotic medication (quetiapine and clozapine) in combination with an acetylcholinesterase inhibitor (rivastigmine). Rivastigmine 232-244 acetylcholinesterase (Cartwright blood group) Homo sapiens 200-220 24239594-0 2014 Preliminary findings of the effects of rivastigmine, an acetylcholinesterase inhibitor, on working memory in cocaine-dependent volunteers. Rivastigmine 39-51 acetylcholinesterase (Cartwright blood group) Homo sapiens 56-76 23408070-4 2013 Donepezil, galantamine and rivastigmine are acetylcholinesterase inhibitors with different pharmacodynamic and pharmacokinetic profiles. Rivastigmine 27-39 acetylcholinesterase (Cartwright blood group) Homo sapiens 44-64 24081314-2 2013 The acetylcholinesterase inhibitors donepezil, rivastigmine, and galantamine and the NMDA-receptor antagonist memantine have produced modest but apparently persistent improvements in cognition, activities of daily living, and behavior in patients with disease severity ranging from mild to severe. Rivastigmine 47-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 24081314-3 2013 Among the acetylcholinesterase inhibitors, transdermal rivastigmine causes fewer gastrointestinal side effects than the oral formulation. Rivastigmine 55-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 10-30 23782591-1 2013 BACKGROUND: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer"s disease (AD). Rivastigmine 86-98 acetylcholinesterase (Cartwright blood group) Homo sapiens 25-45 23557940-1 2013 This study was designed to determine the effect of a potent subcutaneously injected acetylcholinesterase inhibitor, rivastigmine (6mg/animal), on the gonadotropin-releasing hormone (GnRH)/luteinizing hormone (LH) release during inflammation induced by an intravenous lipopolysaccharide (LPS) (400ng/kg) injection in ewes during the follicular phase of the estrous cycle. Rivastigmine 116-128 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-104 23557940-3 2013 Rivastigmine decreased the acetylcholinesterase concentration in the blood plasma from 176.9+-9.5 to 99.3+-15.1mumol/min/ml. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 27-47 23408070-7 2013 Rivastigmine is a so-called "pseudo-irreversible" inhibitor of acetylcholinesterase and butyrylcholinesterase. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 63-83 23229229-3 2013 AChE inhibitors such as rivastigmine, galantamine, physostigmine and huperzine are obtained from plants, indicating that plants can serve as a potential source for novel AChE inhibitors. Rivastigmine 24-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 23610582-2 2013 Rivastigmine, an acetylcholinesterase inhibitor, has several common adverse effects, mainly involving the gastrointestinal tract, but few cardiovascular adverse effects have been reported. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-37 23229229-3 2013 AChE inhibitors such as rivastigmine, galantamine, physostigmine and huperzine are obtained from plants, indicating that plants can serve as a potential source for novel AChE inhibitors. Rivastigmine 24-36 acetylcholinesterase (Cartwright blood group) Homo sapiens 170-174 23672025-3 2013 Compound 8n exhibited the strongest inhibition on acetylcholinesterase (AChE) with an IC50 value of 8.78 micromol x L(-1), and compound 8i showed the most potent inhibition on butyrylcholinesterase (BChE) with IC50 value of 1.60 micromol x L(-1) which was slightly better than rivastigmine. Rivastigmine 277-289 acetylcholinesterase (Cartwright blood group) Homo sapiens 72-76 20193764-2 2010 Of known interventions, psychopharmacology provides readily available options, such as the anti-dementia drugs, e.g. acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine) and memantine. Rivastigmine 174-186 acetylcholinesterase (Cartwright blood group) Homo sapiens 117-137 22391555-7 2013 The use of AChE-ICER in the ligands recognition assay was validated by evaluation of four known reversible inhibitors (galanthamine, tacrine, propidium, and rivastigmine), and the same order of inhibitory potencies described in the literature was found. Rivastigmine 157-169 acetylcholinesterase (Cartwright blood group) Homo sapiens 11-15 22451057-1 2012 A capillary zone electrophoresis-electrospray ionization-mass spectrometry (CZE-ESI-MS) method was developed for the analysis of the acetylcholinesterase inhibitor rivastigmine. Rivastigmine 164-176 acetylcholinesterase (Cartwright blood group) Homo sapiens 133-153 22323348-2 2012 This study was designed to determine the interaction between inhibition of both butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) with rivastigmine and peripheral insulin resistance (IR) in LOAD. Rivastigmine 147-159 acetylcholinesterase (Cartwright blood group) Homo sapiens 114-134 22323348-2 2012 This study was designed to determine the interaction between inhibition of both butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) with rivastigmine and peripheral insulin resistance (IR) in LOAD. Rivastigmine 147-159 acetylcholinesterase (Cartwright blood group) Homo sapiens 136-140 22323348-8 2012 CONCLUSION: In conclusion, inhibition of both BuChE and AChE with rivastigmine was improved the cognition without affecting on the peripheral IR in the elderly patients with LOAD by HOMA. Rivastigmine 66-78 acetylcholinesterase (Cartwright blood group) Homo sapiens 56-60 21624391-3 2011 Thus, this study sought to determine whether rivastigmine, an acetylcholinesterase inhibitor and cognition enhancing agent, could improve neurocognitive performance in a sample of long-term, high-dose methamphetamine addicts who were not seeking treatment at the time of enrollment in the study. Rivastigmine 45-57 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 22778810-5 2010 HLA20A inhibited AChE in a time and concentration dependent manner with an HLA20A-AChE complex constant (K(i)) of 9.66 x 10(-6) M, a carbamylation rate (k(+2)) of 0.14 min(-1), and a second-order rate (k(i)) of 1.45 x 10 (4) M(-1) min(-1), comparable to those of rivastigmine. Rivastigmine 263-275 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-21 22778810-5 2010 HLA20A inhibited AChE in a time and concentration dependent manner with an HLA20A-AChE complex constant (K(i)) of 9.66 x 10(-6) M, a carbamylation rate (k(+2)) of 0.14 min(-1), and a second-order rate (k(i)) of 1.45 x 10 (4) M(-1) min(-1), comparable to those of rivastigmine. Rivastigmine 263-275 acetylcholinesterase (Cartwright blood group) Homo sapiens 82-86 20452337-2 2010 Several AChE inhibitors, e.g. rivastigmine, galantamine and huperzine are originating from plants, suggesting that herbs could potentially serve as sources for novel AChE inhibitors. Rivastigmine 30-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 8-12 20452337-2 2010 Several AChE inhibitors, e.g. rivastigmine, galantamine and huperzine are originating from plants, suggesting that herbs could potentially serve as sources for novel AChE inhibitors. Rivastigmine 30-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 166-170 24291871-7 2013 Rivastigmine increase acetylcholine in the cholinergic synapse by inhibition of both AChE and butyrylcholinesterase. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 22751086-3 2012 This study examined the effects of rivastigmine, a selective central nervous system acetylcholinesterase inhibitor, with benefits on cognition in Alzheimer disease, on memory performance in patients with schizophrenia treated with ECT. Rivastigmine 35-47 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-104 20190429-4 2010 Such dual inhibitors were designed by the hybridization of rivastigmine and fluoxetine based on a hypothetical model of the AChE active site. Rivastigmine 59-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 124-128 19199870-7 2009 Rivastigmine was associated with decreased AChE activity by 42.6% and decreased AChE protein levels by 9.3%, and decreased BuChE activity by 45.6% and decreased BuChE protein levels by 21.8%. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 43-47 21389938-2 2010 Given this conception, we conducted a controlled study of efficacy and safety of acetylcholinesterase inhibitor rivastigmine in patients developed a delirium in the acute phase of ischemic stroke. Rivastigmine 112-124 acetylcholinesterase (Cartwright blood group) Homo sapiens 81-101 18780301-0 2009 Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer"s disease and relationships with response to treatment with Donepezil and Rivastigmine. Rivastigmine 152-164 acetylcholinesterase (Cartwright blood group) Homo sapiens 15-19 18780301-9 2009 Carrying an allele or a genotype of these SNPs does not seem to play a relevant role in the response to treatment with the two cholinesterase inhibitors, though some significant results were found associated with the AChE A/A genotype that had the best response when treated with Rivastigmine. Rivastigmine 280-292 acetylcholinesterase (Cartwright blood group) Homo sapiens 217-221 19199870-7 2009 Rivastigmine was associated with decreased AChE activity by 42.6% and decreased AChE protein levels by 9.3%, and decreased BuChE activity by 45.6% and decreased BuChE protein levels by 21.8%. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 80-84 19199870-11 2009 Changes in mean AChE-Readthrough/Synaptic ratios, which might reflect underlying neurodegenerative processes, were 1.4, 0.6, and 0.4 for rivastigmine, donepezil and galantamine, respectively. Rivastigmine 137-149 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 19199870-13 2009 Rivastigmine provides sustained inhibition of AChE and BuChE, while donepezil and galantamine do not inhibit BuChE and are associated with increases in CSF AChE protein levels. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-50 18692909-0 2008 Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. Rivastigmine 92-104 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-81 18729824-1 2009 The role of the functional architecture of the HuAChE (human acetylcholinesterase) in reactivity toward the carbamates pyridostigmine, rivastigmine and several analogues of physostigmine, that are currently used or considered for use as drugs for Alzheimer"s disease, was analysed using over 20 mutants of residues that constitute the interaction subsites in the active centre. Rivastigmine 135-147 acetylcholinesterase (Cartwright blood group) Homo sapiens 61-81 18692909-1 2008 In this study we determined the influence of cholinergic up-regulation by rivastigmine, an acetylcholinesterase inhibitor, on central nervous system inflammation. Rivastigmine 74-86 acetylcholinesterase (Cartwright blood group) Homo sapiens 91-111 16144975-0 2005 Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. Rivastigmine 100-112 acetylcholinesterase (Cartwright blood group) Homo sapiens 40-60 18207225-0 2008 The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Rivastigmine 35-47 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 18207225-2 2008 We conducted a double-blind, placebo-controlled, between groups investigation of the acetylcholinesterase (AChE) inhibitor rivastigmine in non-treatment-seeking volunteers who met criteria for methamphetamine abuse or dependence. Rivastigmine 123-135 acetylcholinesterase (Cartwright blood group) Homo sapiens 107-111 18042006-3 2007 The acetylcholinesterase inhibitors used to treat AD patients at present are donepezil, rivastigmine and galantamine. Rivastigmine 88-100 acetylcholinesterase (Cartwright blood group) Homo sapiens 4-24 17955784-1 2007 The efficacy of the acetylcholinesterase inhibitors donepezil, galantamine and rivastigmine for Alzheimer"s disease is well-documented by a number of studies. Rivastigmine 79-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 20-40 17724973-2 2007 Presently three AChE inhibitors are approved for the treatment of mild to moderately severe Alzheimer dementia: donepezil, rivastigmine and galantamine. Rivastigmine 123-135 acetylcholinesterase (Cartwright blood group) Homo sapiens 16-20 17303332-2 2007 Alterations of cortical excitability, induced by acute and repeated administration of the acetylcholinesterase inhibitor rivastigmine were investigated with transcranial magnetic stimulation in healthy volunteers. Rivastigmine 121-133 acetylcholinesterase (Cartwright blood group) Homo sapiens 90-110 18044073-7 2007 Rivastigmine (Exelon, Novartis Basel-Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept, Pfizer, New York, USA) and galantamine (Reminyl, Janssen, New Jersey, USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 86-106 18044073-7 2007 Rivastigmine (Exelon, Novartis Basel-Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept, Pfizer, New York, USA) and galantamine (Reminyl, Janssen, New Jersey, USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 108-112 18044073-7 2007 Rivastigmine (Exelon, Novartis Basel-Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept, Pfizer, New York, USA) and galantamine (Reminyl, Janssen, New Jersey, USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 309-313 18044073-7 2007 Rivastigmine (Exelon, Novartis Basel-Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept, Pfizer, New York, USA) and galantamine (Reminyl, Janssen, New Jersey, USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. Rivastigmine 14-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 86-106 18044073-7 2007 Rivastigmine (Exelon, Novartis Basel-Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept, Pfizer, New York, USA) and galantamine (Reminyl, Janssen, New Jersey, USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. Rivastigmine 14-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 108-112 18044073-7 2007 Rivastigmine (Exelon, Novartis Basel-Switzerland) is a slowly reversible inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), while donepezil (Aricept, Pfizer, New York, USA) and galantamine (Reminyl, Janssen, New Jersey, USA) show no functional inhibition of BuChE, and are considered AChE-selective, rapidly-reversible inhibitors. Rivastigmine 14-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 309-313 16574032-16 2006 Analysis of response by BuChE genotype suggests that this differential effect may be due to the inhibition of BuChE, in addition to AChE, by rivastigmine. Rivastigmine 141-153 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-136 16181792-2 2006 In a randomized, placebo-controlled, double-blind, parallel-group design, we investigated the neural correlates of cognitive effects of rivastigmine, an acetylcholinesterase inhibitor, given as an add-on therapy to antipsychotic-treated schizophrenia patients. Rivastigmine 136-148 acetylcholinesterase (Cartwright blood group) Homo sapiens 153-173 18248689-3 2008 We conducted this study in order to determine the safety (adverse events, mood changes, cardiovascular effects) and preliminary efficacy (subjective effects) of the AChE inhibitor rivastigmine (Riv) when tested in combination with Meth. Rivastigmine 180-192 acetylcholinesterase (Cartwright blood group) Homo sapiens 165-169 18248689-3 2008 We conducted this study in order to determine the safety (adverse events, mood changes, cardiovascular effects) and preliminary efficacy (subjective effects) of the AChE inhibitor rivastigmine (Riv) when tested in combination with Meth. Rivastigmine 194-197 acetylcholinesterase (Cartwright blood group) Homo sapiens 165-169 18155915-0 2008 Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes. Rivastigmine 70-82 acetylcholinesterase (Cartwright blood group) Homo sapiens 129-133 18155915-1 2008 Rivastigmine is a newer-generation inhibitor with a dual inhibitory action on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes, and is used for the treatment of AChE- and BChE-related diseases such as brain Alzheimer"s disease and cardiovascular disease. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 83-103 18155915-1 2008 Rivastigmine is a newer-generation inhibitor with a dual inhibitory action on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes, and is used for the treatment of AChE- and BChE-related diseases such as brain Alzheimer"s disease and cardiovascular disease. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 105-109 18155915-1 2008 Rivastigmine is a newer-generation inhibitor with a dual inhibitory action on both acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) enzymes, and is used for the treatment of AChE- and BChE-related diseases such as brain Alzheimer"s disease and cardiovascular disease. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 186-191 17572053-5 2007 Acetylcholinesterase inhibitors may be useful in both these types of dementia: rivastigmine is approved for treating Parkinson disease dementia and clozapine for reducing hallucinations. Rivastigmine 79-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 17660172-2 2007 The purpose of this study was to detect brain perfusion changes and the effects of rivastigmine, an acetylcholinesterase inhibitor on single photon emission computed tomography (SPECT) before and after treatment. Rivastigmine 83-95 acetylcholinesterase (Cartwright blood group) Homo sapiens 100-120 17134713-7 2007 Moreover, noteworthy results were obtained in the application of the AChE-CIM-IMER to the characterization of the carbamoylation and decarbamoylation steps in pseudo-irreversible binding of carbamate derivatives (physostigmine and rivastigmine). Rivastigmine 231-243 acetylcholinesterase (Cartwright blood group) Homo sapiens 69-73 17355738-2 2007 Acetylcholinesterase (AChE) inhibitors, such as rivastigmine, have been shown to improve cognition in other disorders, particularly Alzheimer"s disease. Rivastigmine 48-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 17355738-2 2007 Acetylcholinesterase (AChE) inhibitors, such as rivastigmine, have been shown to improve cognition in other disorders, particularly Alzheimer"s disease. Rivastigmine 48-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 22-26 17047484-11 2006 These differences may reflect rivastigmine"s ability to inhibit BuChE and AChE. Rivastigmine 30-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 74-78 16797163-3 2006 Acetylcholinesterase inhibitors, such as Physostigmine and Rivastigmine, are considered effective treatments for cognitive decline in Alzheimer"s Disease, where the loss of cholinergic neurons is thought to be responsible for various cognitive deficits. Rivastigmine 59-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-20 16373816-1 2006 Rivastigmine, which has been approved by the US Food and Drugs Administration for the treatment of Alzheimer"s disease, is a non-competitive reversible inhibitor of acetylcholinesterase. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 165-185 16307702-3 2005 In addition to acetylcholinesterase (AChE) inhibition, rivastigmine also inhibits butrylcholinesterase (BuChE), providing dual AChE and BuChE inhibition. Rivastigmine 55-67 acetylcholinesterase (Cartwright blood group) Homo sapiens 127-131 16307702-4 2005 An observational study was performed to determine the response in routine clinical practice to switching AD patients to rivastigmine from a selective AChE inhibitor when that treatment no longer delivered a satisfactory clinical response. Rivastigmine 120-132 acetylcholinesterase (Cartwright blood group) Homo sapiens 150-154 16307702-16 2005 CONCLUSIONS: AD patients deteriorating on selective AChE inhibitor treatment can benefit from switching to a dual AChE-BuChE inhibitor, such as rivastigmine, in terms of stabilization of disease, improvement in cognitive function and reduction in the burden of concomitant psychoactive treatment. Rivastigmine 144-156 acetylcholinesterase (Cartwright blood group) Homo sapiens 52-56 16307702-16 2005 CONCLUSIONS: AD patients deteriorating on selective AChE inhibitor treatment can benefit from switching to a dual AChE-BuChE inhibitor, such as rivastigmine, in terms of stabilization of disease, improvement in cognitive function and reduction in the burden of concomitant psychoactive treatment. Rivastigmine 144-156 acetylcholinesterase (Cartwright blood group) Homo sapiens 114-118 16212945-3 2005 The present experiment assessed the ability of rivastigmine, a clinically utilized agent that inhibits acetylcholinesterase and butyrylcholinesterase activities, to inhibit cholinesterases in plaques and tangles. Rivastigmine 47-59 acetylcholinesterase (Cartwright blood group) Homo sapiens 103-123 16212945-10 2005 Rivastigmine inhibited acetylcholinesterase in all positive structures in a dose-dependent manner (10(-6)-10(-4) M). Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 23-43 16212945-13 2005 In conclusion, rivastigmine is a potent inhibitor of acetylcholinesterase and a more potent inhibitor of butyrylcholinesterase in plaques and tangles. Rivastigmine 15-27 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-73 16144975-1 2005 Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently being used to treat patients suffering from Alzheimer"s disease. Rivastigmine 11-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 62-82 16144975-1 2005 Donepezil, rivastigmine, and galantamine are three drugs with acetylcholinesterase (AChE)-inhibiting activity that are currently being used to treat patients suffering from Alzheimer"s disease. Rivastigmine 11-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 15633941-1 2004 The goal of this study was to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effect on delirium in vascular dementia (VaD). Rivastigmine 48-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 104-108 16024879-3 2005 METHODS: We evaluated whether SAI testing, together with SAI test-retest, after a single dose of the acetylcholinesterase (AChE) inhibitor rivastigmine, might be useful in predicting the response after 1 year treatment with rivastigmine in 16 AD patients. Rivastigmine 139-151 acetylcholinesterase (Cartwright blood group) Homo sapiens 101-121 16024879-3 2005 METHODS: We evaluated whether SAI testing, together with SAI test-retest, after a single dose of the acetylcholinesterase (AChE) inhibitor rivastigmine, might be useful in predicting the response after 1 year treatment with rivastigmine in 16 AD patients. Rivastigmine 139-151 acetylcholinesterase (Cartwright blood group) Homo sapiens 123-127 15659242-1 2005 BACKGROUND: Rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for symptomatic treatment of Alzheimer"s disease (AD). Rivastigmine 12-24 acetylcholinesterase (Cartwright blood group) Homo sapiens 28-59 15537349-1 2004 Rivastigmine (1), an acetylcholinesterase (AChE) inhibitor approved in 2000 for the treatment of Alzheimer disease, bears a carbamate moiety in its structure, which is able to react covalently with the active site of the enzyme. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 21-41 15537349-1 2004 Rivastigmine (1), an acetylcholinesterase (AChE) inhibitor approved in 2000 for the treatment of Alzheimer disease, bears a carbamate moiety in its structure, which is able to react covalently with the active site of the enzyme. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 43-47 15486516-2 2004 Because rivastigmine, a reversible acetylcholinesterase inhibitor, appears to delay the progression of Alzheimer"s disease, it may also improve or delay the cognitive and behavioural disturbances evident in elderly chronic schizophrenia patients with comorbid cognitive decline. Rivastigmine 8-20 acetylcholinesterase (Cartwright blood group) Homo sapiens 35-55 15161118-2 2004 Having obtained good results in a previous study comparing rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholine-sterase (BuChE), vs. aspirin, we aimed to compare the efficacy and tolerability of rivastigmine vs. aspirin plus nimodipine. Rivastigmine 59-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 89-109 15304241-1 2004 The therapeutic approach for improving the cognitive function in patients with Alzheimer"s disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. Rivastigmine 280-292 acetylcholinesterase (Cartwright blood group) Homo sapiens 213-233 15304241-1 2004 The therapeutic approach for improving the cognitive function in patients with Alzheimer"s disease (AD) is mainly based on the potentiation of central cholinergic activity and is achieved clinically by the use of acetylcholinesterase (AChE) inhibitors such as tacrine, donepezil, rivastigmine, galantamine and other drugs currently in clinical trials. Rivastigmine 280-292 acetylcholinesterase (Cartwright blood group) Homo sapiens 235-239 15161118-6 2004 The benefits observed with rivastigmine may reflect its inhibitory effects on AChE and BuChE, and the drug"s affinity for frontal brain areas. Rivastigmine 27-39 acetylcholinesterase (Cartwright blood group) Homo sapiens 78-82 15163283-3 2004 Based on limited open-labelled controlled studies of rivastigmine in VaD, this article aims to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effects on the typical symptoms of subcortical VaD. Rivastigmine 113-125 acetylcholinesterase (Cartwright blood group) Homo sapiens 169-173 15161118-2 2004 Having obtained good results in a previous study comparing rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholine-sterase (BuChE), vs. aspirin, we aimed to compare the efficacy and tolerability of rivastigmine vs. aspirin plus nimodipine. Rivastigmine 59-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 111-115 15544502-3 2004 Effectiveness in AChE inhibition and side-effect issues of clinical (tacrine, donepezil, galanthamine and rivastigmine) as well as of novel inhibitors is reviewed here. Rivastigmine 106-118 acetylcholinesterase (Cartwright blood group) Homo sapiens 17-21 15222774-4 2004 Post-hoc analyses of rivastigmine and galantamine in patients with more advanced Alzheimer"s disease have supported the hypothesis that acetylcholinesterase inhibitors are likely be efficacious in this subgroup. Rivastigmine 21-33 acetylcholinesterase (Cartwright blood group) Homo sapiens 136-156 15544507-2 2004 Thus, it is not surprising that the first therapeutic target that has demonstrated therapeutic efficacy on cognition, behaviour and functional daily activities has been the inhibitors of acetylcholinesterase (AChE), i.e. tacrine, donepezil, rivastigmine and galanthamine. Rivastigmine 241-253 acetylcholinesterase (Cartwright blood group) Homo sapiens 187-207 15544507-2 2004 Thus, it is not surprising that the first therapeutic target that has demonstrated therapeutic efficacy on cognition, behaviour and functional daily activities has been the inhibitors of acetylcholinesterase (AChE), i.e. tacrine, donepezil, rivastigmine and galanthamine. Rivastigmine 241-253 acetylcholinesterase (Cartwright blood group) Homo sapiens 209-213 15544507-4 2004 For instance, rivastigmine is a dual inhibitor of AChE and butyrylcholinesterase (BuChE), and galanthamine is a mild inhibitor of AChE and an allosteric potentiating ligand of neuronal nicotinic receptors for acetylcholine (nAChRs). Rivastigmine 14-26 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-54 15132713-4 2004 There is substantial evidence that the cholinesterase inhibitors, including donepezil, galantamine and rivastigmine, decrease acetylcholinesterase activity in a number of brain regions in patients with Alzheimer"s disease. Rivastigmine 103-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 126-146 14573772-8 2003 Unlike galantamine, the acetylcholinesterase inhibitors rivastigmine and donepezil did not potentiate nAChR-mediated responses, whereas donepezil was a reasonably potent inhibitor of nicotine- and KCl-evoked increases in Ca2+. Rivastigmine 56-68 acetylcholinesterase (Cartwright blood group) Homo sapiens 24-44 15554751-1 2004 OBJECTIVE: This preliminary open-label study aims to investigate the effects of rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), in 20 patients diagnosed with frontotemporal dementia (FTD). Rivastigmine 80-92 acetylcholinesterase (Cartwright blood group) Homo sapiens 110-130 15554751-1 2004 OBJECTIVE: This preliminary open-label study aims to investigate the effects of rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), in 20 patients diagnosed with frontotemporal dementia (FTD). Rivastigmine 80-92 acetylcholinesterase (Cartwright blood group) Homo sapiens 132-136 14646612-1 2003 We aimed to determine whether the cholinesterase inhibitor rivastigmine, an inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), would improve quality of life and cognitive function in 16 clinically stable subjects affected by schizophrenia in the residual phase. Rivastigmine 59-71 acetylcholinesterase (Cartwright blood group) Homo sapiens 111-115 14569643-2 2003 This study aimed to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyryl-cholinesterase (BuChE), has any effects on the typical symptoms of subcortical VaD. Rivastigmine 38-50 acetylcholinesterase (Cartwright blood group) Homo sapiens 94-98 24944370-1 2003 BACKGROUND: Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer"s disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine. Rivastigmine 252-264 acetylcholinesterase (Cartwright blood group) Homo sapiens 134-138 15088511-2 2003 The approach to the treatment of Alzheimer"s dementia has been greatly modified by the acetylcholinesterase inhibitor drugs, first donepezil (Aricept) and then rivastigmine (Exelon) and galantamine (Reminyl), and the ever-increasing number of demented people forces us to be familiar with their use. Rivastigmine 174-180 acetylcholinesterase (Cartwright blood group) Homo sapiens 87-107 12450245-4 2002 More recent investigations have assessed acetylcholinesterase (AChE) and cholinesterase (ChE) inhibitors such as donepezil, rivastigmine and galantamine. Rivastigmine 124-136 acetylcholinesterase (Cartwright blood group) Homo sapiens 41-61 14687441-6 2003 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Rivastigmine 79-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 208-228 14687441-6 2003 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Rivastigmine 79-91 acetylcholinesterase (Cartwright blood group) Homo sapiens 230-234 14687441-6 2003 A number of open-label studies, where patients were switched from donepezil to rivastigmine, have indicated that approximately 50% of patients experiencing a lack/loss of efficacy with donepezil (a selective acetylcholinesterase [AChE] inhibitor) respond to subsequent treatment with rivastigmine (a dual AChE and butyrylcholinesterase inhibitor). Rivastigmine 284-296 acetylcholinesterase (Cartwright blood group) Homo sapiens 230-234 12454562-1 2002 Donepezil and rivastigmine are acetylcholinesterase (AChE) inhibitors used to improve cholinergic neurotransmission and cognitive function in Alzheimer"s disease (AD). Rivastigmine 14-26 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-57 12454562-10 2002 The present study provides first evidence for the effect of rivastigmine on cortical AChE activity. Rivastigmine 60-72 acetylcholinesterase (Cartwright blood group) Homo sapiens 85-89 12454562-11 2002 Our results indicate that the pooled effects of donepezil and rivastigmine on brain AChE are greater in the frontal cortex compared to the temporal cortex in AD. Rivastigmine 62-74 acetylcholinesterase (Cartwright blood group) Homo sapiens 84-88 14535624-8 2003 Only one inhibitor, rivastigmine, displayed preferential inhibition for the G1 form of AChE. Rivastigmine 20-32 acetylcholinesterase (Cartwright blood group) Homo sapiens 87-91 12417373-1 2002 Further to recent data indicating that patients with vascular dementia (VaD) show a cholinergic deficit, we aimed to determine whether rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), has any effects on the symptoms of VaD. Rivastigmine 135-147 acetylcholinesterase (Cartwright blood group) Homo sapiens 191-195 12469000-5 2002 We report the case of a patient with PD and cognitive impairment who developed a marked worsening of motor function, mood, and anxiety in the setting of a pharmacologic challenge study using a 3-mg oral dose of the acetylcholinesterase inhibitor, rivastigmine. Rivastigmine 247-259 acetylcholinesterase (Cartwright blood group) Homo sapiens 215-235 12548360-3 2002 AChE activity in CSF was significantly increased after treatment with donepezil and galantamine; the opposite was observed in the rivastigmine-treated group. Rivastigmine 130-142 acetylcholinesterase (Cartwright blood group) Homo sapiens 0-4 11888271-1 2002 Rivastigmine, a carbamate inhibitor of acetylcholinesterase, is already in use for treatment of Alzheimer"s disease under the trade name of Exelon. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 39-59 12196650-1 2002 OBJECTIVE: To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD. Rivastigmine 61-73 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 12196650-1 2002 OBJECTIVE: To study the long-term dual inhibitory effects of rivastigmine on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in patients with AD. Rivastigmine 61-73 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-103 12196650-10 2002 CONCLUSIONS: Rivastigmine causes persistent inhibition of AChE and BuChE in CSF as well as plasma. Rivastigmine 13-25 acetylcholinesterase (Cartwright blood group) Homo sapiens 58-62 12111443-2 2002 This multiple-dose study has examined the relationship between inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in the cerebrospinal fluid (CSF) and cognitive change (measured by the Computerised Neuropsychological Test Battery [CNTB]) following administration of the ChE inhibitor, rivastigmine (Exelon). Rivastigmine 321-333 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 12111443-2 2002 This multiple-dose study has examined the relationship between inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in the cerebrospinal fluid (CSF) and cognitive change (measured by the Computerised Neuropsychological Test Battery [CNTB]) following administration of the ChE inhibitor, rivastigmine (Exelon). Rivastigmine 321-333 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-103 12111443-2 2002 This multiple-dose study has examined the relationship between inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in the cerebrospinal fluid (CSF) and cognitive change (measured by the Computerised Neuropsychological Test Battery [CNTB]) following administration of the ChE inhibitor, rivastigmine (Exelon). Rivastigmine 335-341 acetylcholinesterase (Cartwright blood group) Homo sapiens 77-97 12111443-2 2002 This multiple-dose study has examined the relationship between inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities in the cerebrospinal fluid (CSF) and cognitive change (measured by the Computerised Neuropsychological Test Battery [CNTB]) following administration of the ChE inhibitor, rivastigmine (Exelon). Rivastigmine 335-341 acetylcholinesterase (Cartwright blood group) Homo sapiens 99-103 12111443-7 2002 CSF samples were continuously collected together with plasma samples prior to and for 12 hours after the final dose of rivastigmine, and AChE and BuChE activities determined.AChE in CSF and BuChE in plasma were dose-dependently inhibited by rivastigmine treatment. Rivastigmine 119-131 acetylcholinesterase (Cartwright blood group) Homo sapiens 174-178 12111443-7 2002 CSF samples were continuously collected together with plasma samples prior to and for 12 hours after the final dose of rivastigmine, and AChE and BuChE activities determined.AChE in CSF and BuChE in plasma were dose-dependently inhibited by rivastigmine treatment. Rivastigmine 241-253 acetylcholinesterase (Cartwright blood group) Homo sapiens 174-178 12139365-4 2002 The dual acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitor rivastigmine was shown to have several potential advantages over the AChE-selective inhibitors donepezil and galantamine for the treatment of BPSD. Rivastigmine 75-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 53-57 12139365-4 2002 The dual acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitor rivastigmine was shown to have several potential advantages over the AChE-selective inhibitors donepezil and galantamine for the treatment of BPSD. Rivastigmine 75-87 acetylcholinesterase (Cartwright blood group) Homo sapiens 144-148 12139365-9 2002 Dual inhibition of AChE and BuChE and brain-region selectivity through preferential inhibition of the G1 isoform of AChE may provide the underlying reasons for the apparently greater and broader efficacy of rivastigmine over AChE-selective inhibitors for the treatment of BPSD. Rivastigmine 207-219 acetylcholinesterase (Cartwright blood group) Homo sapiens 19-23 12139365-9 2002 Dual inhibition of AChE and BuChE and brain-region selectivity through preferential inhibition of the G1 isoform of AChE may provide the underlying reasons for the apparently greater and broader efficacy of rivastigmine over AChE-selective inhibitors for the treatment of BPSD. Rivastigmine 207-219 acetylcholinesterase (Cartwright blood group) Homo sapiens 116-120 12139365-9 2002 Dual inhibition of AChE and BuChE and brain-region selectivity through preferential inhibition of the G1 isoform of AChE may provide the underlying reasons for the apparently greater and broader efficacy of rivastigmine over AChE-selective inhibitors for the treatment of BPSD. Rivastigmine 207-219 acetylcholinesterase (Cartwright blood group) Homo sapiens 116-120 12139366-2 2002 New research suggests that rivastigmine, a potent, pseudo-irreversible inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase that shows preferential selectivity for the G1 form of AChE, may provide symptomatic and disease progression slowing effects. Rivastigmine 27-39 acetylcholinesterase (Cartwright blood group) Homo sapiens 89-109 12139366-2 2002 New research suggests that rivastigmine, a potent, pseudo-irreversible inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase that shows preferential selectivity for the G1 form of AChE, may provide symptomatic and disease progression slowing effects. Rivastigmine 27-39 acetylcholinesterase (Cartwright blood group) Homo sapiens 111-115 12139366-2 2002 New research suggests that rivastigmine, a potent, pseudo-irreversible inhibitor of both acetylcholinesterase (AChE) and butyrylcholinesterase that shows preferential selectivity for the G1 form of AChE, may provide symptomatic and disease progression slowing effects. Rivastigmine 27-39 acetylcholinesterase (Cartwright blood group) Homo sapiens 198-202 12139367-3 2002 These events have been associated more with the dual acetylcholinesterase/butyrylcholinesterase (AChE/BuChE) inhibitor rivastigmine than with the AChE-selective inhibitors donepezil and galantamine, probably due to rivastigmine"s higher potency. Rivastigmine 119-131 acetylcholinesterase (Cartwright blood group) Homo sapiens 97-101 12139368-4 2002 Tacrine and rivastigmine inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the CSF of Alzheimer"s disease patients. Rivastigmine 12-24 acetylcholinesterase (Cartwright blood group) Homo sapiens 38-58 12139368-4 2002 Tacrine and rivastigmine inhibit both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the CSF of Alzheimer"s disease patients. Rivastigmine 12-24 acetylcholinesterase (Cartwright blood group) Homo sapiens 60-64 12018828-3 2002 Rivastigmine is a potent inhibitor of AChE and BuChE and has demonstrated broad benefits across the severity of AD and across the cognitive, functional and behavioural domains of AD. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 38-42 12018828-5 2002 These benefits may reflect the inhibition of both AChE and BuChE, as demonstrated by significant correlations between cognitive improvements and cholinesterase inhibition in rivastigmine-treated patients with AD. Rivastigmine 174-186 acetylcholinesterase (Cartwright blood group) Homo sapiens 50-54 11888271-1 2002 Rivastigmine, a carbamate inhibitor of acetylcholinesterase, is already in use for treatment of Alzheimer"s disease under the trade name of Exelon. Rivastigmine 140-146 acetylcholinesterase (Cartwright blood group) Homo sapiens 39-59 11888271-2 2002 Rivastigmine carbamylates Torpedo californica acetylcholinesterase very slowly (k(i) = 2.0 M(-1) min(-1)), whereas the bimolecular rate constant for inhibition of human acetylcholinesterase is >1600-fold higher (k(i) = 3300 M(-1) min(-1)). Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 46-66 11888271-2 2002 Rivastigmine carbamylates Torpedo californica acetylcholinesterase very slowly (k(i) = 2.0 M(-1) min(-1)), whereas the bimolecular rate constant for inhibition of human acetylcholinesterase is >1600-fold higher (k(i) = 3300 M(-1) min(-1)). Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 169-189 11888271-4 2002 Spontaneous reactivation of all four conjugates is very slow, with <10% reactivation being observed for the Torpedo enzyme after 48 h. The crystal structure of the conjugate of rivastigmine with Torpedo acetylcholinesterase was determined to 2.2 A resolution. Rivastigmine 180-192 acetylcholinesterase (Cartwright blood group) Homo sapiens 206-226 12240787-4 2002 Here, we present a case series of patients with Parkinson"s disease and dementia who we treated with rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) that shows brain region-selectivity. Rivastigmine 101-113 acetylcholinesterase (Cartwright blood group) Homo sapiens 135-155 12240787-4 2002 Here, we present a case series of patients with Parkinson"s disease and dementia who we treated with rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) that shows brain region-selectivity. Rivastigmine 101-113 acetylcholinesterase (Cartwright blood group) Homo sapiens 157-161 12240787-6 2002 Rivastigmine was well tolerated by our patients when the dose was escalated slowly, including one patient who had previously experienced severe side-effects with the AChE-selective inhibitor donepezil. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 166-170 12636178-12 2002 Rivastigmine robustly inhibits butyrylcholinesterase in addition to AChE and therefore acts as a dual ChE inhibitor. Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 68-72 12636181-5 2002 Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Rivastigmine 159-171 acetylcholinesterase (Cartwright blood group) Homo sapiens 143-147 12636181-5 2002 Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine analogues, MF-8622) and the dual inhibitor of both AChE and BuChE, rivastigmine, indicates potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Rivastigmine 159-171 acetylcholinesterase (Cartwright blood group) Homo sapiens 233-237 11336614-1 2001 Rivastigmine (Exelontrade mark, Novartis) is a novel intermediate-acting reversible and non-competitive carbamate acetylcholinesterase (AChE) that was recently introduced for the treatment of Alzheimer"s disease (AD). Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 114-134 11669506-8 2001 Conventional AChE inhibitors (rivastigmine and donepezil) have maintained ADAS-cog baseline scores for up to 40 weeks in open extension studies, and Mini-Mental State Examination (MMSE) scores for up to 52 weeks in a placebo-controlled study. Rivastigmine 30-42 acetylcholinesterase (Cartwright blood group) Homo sapiens 13-17 19811047-3 2001 The three new acetylcholinesterase inhibitors licensed to treat Alzheimer"s disease (donepezil, rivastigmine and galantamine) have provided clinicians with a major impetus to their desire to diagnose and treat this lethal disease. Rivastigmine 96-108 acetylcholinesterase (Cartwright blood group) Homo sapiens 14-34 11336614-1 2001 Rivastigmine (Exelontrade mark, Novartis) is a novel intermediate-acting reversible and non-competitive carbamate acetylcholinesterase (AChE) that was recently introduced for the treatment of Alzheimer"s disease (AD). Rivastigmine 0-12 acetylcholinesterase (Cartwright blood group) Homo sapiens 136-140 11186600-13 2000 A study of rivastigmine in patients with Alzheimer disease revealed that cerebrospinal fluid AChE inhibition correlated well with cognitive performance, whereas peripheral inhibition did not. Rivastigmine 11-23 acetylcholinesterase (Cartwright blood group) Homo sapiens 93-97 11900310-9 2001 Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine, MF-8622) and ChE inhibitors such as rivastigmine, which have a dual inhibitory action on both AChE and BuChE, indicate potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Rivastigmine 129-141 acetylcholinesterase (Cartwright blood group) Homo sapiens 187-191 11900310-9 2001 Experimental evidence from the use of agents with enhanced selectivity for BuChE (cymserine, MF-8622) and ChE inhibitors such as rivastigmine, which have a dual inhibitory action on both AChE and BuChE, indicate potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias. Rivastigmine 129-141 acetylcholinesterase (Cartwright blood group) Homo sapiens 262-266 11078030-1 2000 Three new cholinesterase inhibitors, donepezil, rivastigmine, and galantamine, all inhibit the enzyme AChE. Rivastigmine 48-60 acetylcholinesterase (Cartwright blood group) Homo sapiens 102-106 11256231-3 2000 The maximum ChE inhibition by physostigmine developed within 30-60 min, while the inhibitory effect of rivastigmine on AChE and BuChE activities reached its peak after 48 and 6 h, respectively. Rivastigmine 103-115 acetylcholinesterase (Cartwright blood group) Homo sapiens 119-123 11256231-4 2000 The order of inhibitory potency (IC50) towards AChE activity under optimal assay conditions for each ChE inhibitor was: physostigmine (0.67 nM) > rivastigmine (4.3 nM) > donepezil (6.7 nM) > TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nM). Rivastigmine 146-158 acetylcholinesterase (Cartwright blood group) Homo sapiens 47-51